» Articles » PMID: 29389890

P450 Pharmacogenetics in Indigenous North American Populations

Overview
Journal J Pers Med
Date 2018 Feb 2
PMID 29389890
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Indigenous North American populations, including American Indian and Alaska Native peoples in the United States, the First Nations, Métis and Inuit peoples in Canada and Amerindians in Mexico, are historically under-represented in biomedical research, including genomic research on drug disposition and response. Without adequate representation in pharmacogenetic studies establishing genotype-phenotype relationships, Indigenous populations may not benefit fully from new innovations in precision medicine testing to tailor and improve the safety and efficacy of drug treatment, resulting in health care disparities. The purpose of this review is to summarize and evaluate what is currently known about cytochrome genetic variation in Indigenous populations in North America and to highlight the importance of including these groups in future pharmacogenetic studies for implementation of personalized drug therapy.

Citing Articles

Perspectives on Using Pharmacogenomics to Guide Tobacco Cessation: Survey Results From an American Indian Community.

Wichman M, Wall D, Garcia Mota S, Killam S, Brown K, Aagaard K Clin Transl Sci. 2025; 18(3):e70194.

PMID: 40078094 PMC: 11904310. DOI: 10.1111/cts.70194.


Comparing the clinical utility of pharmacogenomic genotyping and next generation sequencing in a military health system adult medicine clinic.

Saunders D, Hellwig L, Pagani A, De Castro M, Haigney M, Poon L Pharmacogenomics. 2025; 25(16-18):637-645.

PMID: 39981562 PMC: 11901368. DOI: 10.1080/14622416.2025.2466413.


A Systematic Review Exploring Empirical Pharmacogenomics Research Within Global Indigenous Populations.

Nasir B, Vinayagam R, Massi L, Nagaraj S, Toombs M, Rae K Mol Genet Genomic Med. 2024; 12(10):e70018.

PMID: 39435544 PMC: 11494250. DOI: 10.1002/mgg3.70018.


Use of Cognitive Interviews in the Development of a Survey Assessing American Indian and Alaska Native Adult Perspectives on Genetics and Biological Specimens.

Hiratsuka V, Beans J, Byars C, Yracheta J, Spicer P Int J Environ Res Public Health. 2024; 21(9).

PMID: 39338028 PMC: 11430884. DOI: 10.3390/ijerph21091144.


Implementing community-engaged pharmacogenomics in Indigenous communities.

Claw K, Dorr C, Woodahl E Nat Commun. 2024; 15(1):920.

PMID: 38296967 PMC: 10831049. DOI: 10.1038/s41467-024-45032-5.


References
1.
Sim S, Risinger C, Dahl M, Aklillu E, Christensen M, Bertilsson L . A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79(1):103-13. DOI: 10.1016/j.clpt.2005.10.002. View

2.
Guengerich F . Cytochrome p450 and chemical toxicology. Chem Res Toxicol. 2007; 21(1):70-83. DOI: 10.1021/tx700079z. View

3.
Miles J, McLaren A, Forrester L, Glancey M, Lang M, Wolf C . Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J. 1990; 267(2):365-71. PMC: 1131297. DOI: 10.1042/bj2670365. View

4.
Hustert E, Haberl M, Burk O, Wolbold R, He Y, Klein K . The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001; 11(9):773-9. DOI: 10.1097/00008571-200112000-00005. View

5.
Salazar-Flores J, Torres-Reyes L, Martinez-Cortes G, Rubi-Castellanos R, Sosa-Macias M, Munoz-Valle J . Distribution of CYP2D6 and CYP2C19 polymorphisms associated with poor metabolizer phenotype in five Amerindian groups and western Mestizos from Mexico. Genet Test Mol Biomarkers. 2012; 16(9):1098-104. PMC: 3438817. DOI: 10.1089/gtmb.2012.0055. View